Delivery Order 36F79721D0166-36C26022F0215
Award Date
6/1/22
Potential Completion Date
5/31/23
Potential Value
$113K
Federal Agency
Veterans Integrated Service Network 20
Awardee
Biocryst Pharmaceuticals Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Durham, NC 27703, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
Biocryst Pharmaceuticals, Inc. was awarded an $85,080.60 delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 20. The firm fixed price order is for the drug BEROTRALSTAT (ORLADEYO) 150MG and has a completion date of June 30, 2022. The contract utilizes Federal Supply Schedule 61-IB and does not have a set-aside designation. Biocryst Pharmaceuticals will deliver the...
This federal contract award is for the delivery of the pharmaceutical product ORLADEYO (berotralstat) to the Department of Veterans Affairs (VA) through the Veterans Integrated Service Network 20 (VISN 20). The prime contractor is Biocryst Pharmaceuticals Inc., a biotechnology company that specializes in developing small molecule drugs for rare diseases. The contract is a delivery order under Biocryst's Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs, which has a ceiling...
The U.S. Department of Veterans Affairs (VA) awarded a $76,896.72 firm fixed-price delivery order to Horizon Therapeutics USA, Inc. for the specialty pharmaceutical KRYSTEXXA 8MG. The award is part of Horizon's Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB) and is placed by the VA's Veterans Integrated Service Network (VISN) 5. This delivery order supports the VA's mission to provide comprehensive healthcare services to the veteran population, as KRYSTEXXA is...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 5 awarded a $59,142.04 delivery order to Horizon Therapeutics USA Inc. under the Pharmaceuticals and Drugs Federal Supply Schedule contract. The delivery order is for the drug KRYSTEXXA 8MG, with a completion date of November 3, 2021. The contract was awarded on November 2, 2021 and utilizes a firm fixed price pricing structure. Performance will take place in La Vergne, Tennessee. No...
This is a $65,686.15 firm fixed-price delivery order awarded by the U.S. Department of Veterans Affairs (VA) to Horizon Therapeutics USA Inc. under the company's $25 million Multiple Award Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB). The order is for KRYSTEXXA 8MG/ML, a specialty pharmaceutical used to treat chronic gout. Horizon Therapeutics is a global biotechnology firm that provides critical medications to support healthcare services for veterans through the VA's Veterans...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 5 awarded a $88,713.06 firm fixed price delivery order to Horizon Therapeutics USA Inc. under the Pharmaceuticals and Drugs Federal Supply Schedule contract. The order is for KRYSTEXXA 8MG medication with a completion date of November 17, 2021. Placed against GSA Schedule FSS-61-IB, the delivery order utilizes the pre-competed pricing structure of the multiple award schedule to procure the...
This is a delivery order awarded by the U.S. Department of Veterans Affairs (VA) to CSL Behring L.L.C., a global biotherapeutics company, for the provision of the emergency blood product Berinert. The contract has a ceiling value of $78,796.08 and is a firm fixed price delivery order issued under CSL Behring's existing Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB), which has a total ceiling value of $201,482,280 and is valid through September 2026. The...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 20 awarded a $198,704.64 delivery order to Horizon Therapeutics USA Inc. under the Pharmaceuticals and Drugs Federal Supply Schedule contract (FSS-61-IB). The firm fixed price order is for the purchase of PEGLOTICASE (KRYSTEXXA) 8MG/ML 75987-0080-10, with a completion date of November 30, 2022. The contract has no set-aside designation and calls for the delivery of pharmaceutical products to...
This is a delivery order awarded by the U.S. Department of Veterans Affairs (VA) to Bristol-Myers Squibb Company, a global biopharmaceutical company, for the supply of the cancer treatment drug BREYANZI. The $335,042.65 firm fixed price contract runs through March 16, 2026 and supports the VA's mission of providing advanced medical therapies to eligible veterans, particularly in the area of oncology and specialized immunotherapy treatments.
The contract is issued under Bristol-Myers Squibb's...
The Department of Veterans Affairs Veterans Health Administration awarded a $653,022 delivery order to Neurocrine Biosciences, Inc. under the company's Pharmaceuticals and Drugs GSA Schedule contract. The order is to refill pharmaceutical items in support of the Veterans Integrated Service Network 12's Continued Management of Pharmacy Operations and Services needs. Performance will take place in San Diego, California over an eight-day period concluding on August 27, 2021. The firm fixed price...